In a significant development within the realm of HIV research, a 62-year-old man from Toronto, referred to as the “Toronto patient,” may soon join the ranks of individuals who have achieved a functional cure for HIV. Following a bone marrow transplant aimed at treating acute myelogenous leukemia, the patient has seen remarkable results, with the immunodeficiency virus now in remission. This extraordinary case was presented at the Canadian Association of HIV Research Conference held in Winnipeg.
A Life-Changing Treatment Journey
The Toronto patient was diagnosed with HIV in 1999 and had been managing the virus with antiretroviral therapy (ART) for nearly 27 years. However, in 2021, he faced a new health challenge: a diagnosis of acute myelogenous leukemia. To combat this aggressive form of cancer, he underwent a bone marrow transplant at the Princess Margaret Cancer Centre, part of the University Health Network.
The transplant involved donor stem cells that were specifically chosen for their possession of a rare genetic mutation known as “delta-32.” According to health officials from Unity Health Toronto and the University of Toronto, individuals with this mutation are resistant to HIV infection due to the absence of a receptor protein encoded by the CCR5 gene, which HIV typically targets to enter immune cells.
Dr. Mario Ostrowski, a clinician-scientist at St. Michael’s Hospital, emphasised the rarity of this genetic trait. “One per cent of people of European ethnicity have bone marrows that are resistant to HIV infection. A bone marrow transplant from these donors can provide a potential cure,” he stated.
The Successful Transplant Outcome
Following the transplant, which involved a global search for the ideal donor match, the Toronto patient’s immune system underwent a complete overhaul. Dr. Jonas Mattson, from the Princess Margaret Cancer Centre, explained the rigorous matching process, which involved checking for familial matches before expanding the search to global databases containing around 47 million potential donors. Ultimately, three compatible donors carrying the delta-32 mutation were identified.
Dr. Mattson highlighted the dual success of the procedure: “The patient’s old immune system was completely gone and replaced by this new immune system, and the cancer was gone. But the interesting thing is also that this new system was resistant to HIV, meaning that the patient couldn’t get infected or get his cells, the new cells infected.”
As of April 2026, the Toronto patient has achieved sustained remission, with HIV levels undetectable. Should he remain in this state for an additional two-and-a-half years after ceasing ART in July 2025, he will be considered cured of HIV.
Caution Amid Optimism
Despite the promising nature of this case, experts urge caution regarding its implications for wider HIV treatment strategies. Dr. Tommy Alfaro Moya from the Princess Margaret Cancer Centre remarked, “This is not a procedure that you would get to get rid of your HIV. This was a very wonderful, extraordinary outcome of the transplant, but it was not the primary outcome why this individual got a transplant.”
Dr. Sharon Walmsley, director of the HIV clinic at UHN, echoed this sentiment, noting the importance of further research and the need for more registered donors. “The thing is, this particular mutation is fairly rare, so there really did require an international search in order to find the bone marrow that had the right mutation that would allow this patient to be cured from their HIV,” she explained.
The Call for Donor Registration
This case not only highlights a potential avenue for curing HIV but also underscores the critical need for individuals to register as bone marrow donors. Dr. Walmsley emphasised that such registrations could lead to breakthroughs in HIV treatment and help combat the stigma still associated with the virus.
As researchers continue to investigate ways to eliminate HIV from the human body, stories like that of the Toronto patient serve as a beacon of hope. They illustrate the profound impact that genetic diversity and donor availability can have on the future of treatments and the lives of patients battling not only cancer but also chronic viral infections.
Why it Matters
The implications of the Toronto patient’s case extend far beyond personal health. As we witness advancements in HIV treatment and potential cures, it becomes increasingly vital to foster a culture of donor registration and awareness. This not only enhances the chances for patients in need of transplants but also contributes to a growing pool of knowledge that could pave the way for innovative therapies. Achieving a cure for HIV remains a formidable challenge, but every step forward, as exemplified by this case, brings us closer to transforming the lives of millions affected by the virus worldwide.
